PRO-MSACTIVE baseline patient reported outcomes (PROs): A phase IV study evaluating ocrelizumab in active relapsing multiple sclerosis

Category Primary study
JournalEuropean Journal of Neurology
Year 2020
This article has no abstract
Epistemonikos ID: a5d6c876ad5e75c9993861a7b18b01e6923fc180
First added on: Feb 12, 2025